

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Frailty, intensive care, social distancing, and telehealth

Peer reviewed journals featured

- A multicentre cohort study on the effect of frailty on survival in patients with COVID-19 [here](#)
- A systematic review and meta-analysis of outcomes from intensive care [here](#)
- Reflecting on experiences of social distancing [here](#)
- An editorial on the social and health consequences of prolonged school closures [here](#)
- US Veterans Health Administration expansion telehealth services during COVID-19 [here](#)
- A modelling study assessing the potential of the COVIDSafe app to sustained control [here](#)
- A survey on the use of cardiac tele-rehabilitation during COVID-19 in Belgium [here](#)
- A rapid review of the early responses of neurosurgical practice to the COVID-19 pandemic [here](#)
- A narrative review on changes in clinical guidelines of gestational diabetes screening and management during COVID-19 outbreak [here](#)
- A case study on application of a system theory model for rapid adoption of existing telehealth technologies during COVID-19 [here](#)
- A brief communication on the overlap of pathophysiology of cystic fibrosis and COVID-19 [here](#)
- Commentary on whether doctors tackling COVID-19 should be immune from negligence claims [here](#)

Letters and correspondence discussed:

- Identification of inhibitory immune checkpoints on natural killer cells in COVID-19 [here](#)
- Questioning studies on droplets and aerosols generated by human speech [here](#)
- A spotlight on child abuse and neglect response in the time of COVID-19 [here](#)
- A letter outlining an Australian survey on the willingness to vaccinate against COVID-19 [here](#)

Pre-peer review papers feature

- A retrospective analysis of social distancing causally impacting the spread of SARS-CoV-2 [here](#)

Guidance and reports

- Cochrane has updated its special collection with an update on antibody tests for identification of current and past infection with SARS-CoV-2 [here](#)

News and blogs

- Blog on partner violence during COVID-19 and expanding our understanding of safety [here](#)
- News feature from Nature on a race to determine what drives COVID-19 severity [here](#)

Twitter

Trending overnight from several media outlets was the news that the US government is buying most of the global supply of remdesivir from the US pharmaceutical company Gilead for the next three months [here](#), [here](#) and [here](#)

@Gileadsciences have released the pricing in an open letter [here](#), which has raised criticism that the cost will be US\$3,200 for a six day treatment, compared to the cost of production of remdesivir estimated to be US\$6 for a six day course treatment. Fair and equitable access as well as profiteering have been raised as major issues. Some remdesivir has been reported to have been provided to Australia's stockpile [here](#). Remdesivir is associated with clinical improvements in some of the outcomes and fewer serious adverse events [here](#)

@theMJA insights on Melbourne's COVID-19 second wave exposes multicultural 'data hole' [here](#)

@hospiceUK on how has COVID-19 affected grief and bereavement [here](#)